Smokers Get Sick Of Colorectal Cancer Earlier.
A callow swat has uncovered a strong link between smoking and the development of precancerous polyps called non-reflective adenomas in the large intestine, a finding that researchers say may explain the earlier onset of colorectal cancer in the midst smokers. Flat adenomas are more aggressive and harder to spot than the raised polyps that are typically detectable during column colorectal screenings, the authors noted. This fact, coupled with their affiliation with smoking, could also explain why colorectal cancer is usually caught at a more advanced stage and at a younger maturity among smokers than nonsmokers.
So "Little is known regarding the risk factors for these boring lesions, which may account for over one-half of all adenomas detected with a high-definition colonoscope," study author Dr Joseph C Anderson, of the Neag Comprehensive Cancer Center at the University of Connecticut Health Center, said in a talk manumitting from the American Society for Gastrointestinal Endoscopy. But, "smoking has been shown to be an distinguished risk factor for colorectal neoplasia tumor formation in several screening studies".
Showing posts with label adenomas. Show all posts
Showing posts with label adenomas. Show all posts
Friday 27 December 2019
Friday 26 August 2016
Statins Do Not Reduce The Risk Of Colon Cancer
Statins Do Not Reduce The Risk Of Colon Cancer.
Statins don't take down the hazard of colorectal cancer, and may even increase the chances of developing precancerous polyps, unusual research suggests. Statins are widely prescribed cholesterol-lowering drugs sold in a contrast of generic forms and brand names, including Lipitor, Crestor and Zocor.
Yet, researchers stressed that the results are "not conclusive," and that man taking statins to lower cholesterol and reduce their peril of heart attack should continue taking the drugs. "We found patients in this study taking statins for more than three years tended to arise more premalignant colon lesions," said study author Dr Monica Bertagnolli, principal of the division of surgical oncology at Brigham and Women's Hospital and a professor of surgery at Harvard Medical School. "This is an gripping finding that needs to be followed up, but it should not raise alarm. No one should dam taking their statins."
The study is to be presented Monday at the American Association for Cancer Research annual engagement in Washington, DC, and it is also published online in the journal Cancer Prevention Research. The figures used in the analysis was from an earlier clinical trial to determine if the cox-2 sedative celecoxib (Celebrex) could be used to prevent colon cancer.
That trial included 2035 folk who were at high risk of colon cancer and had already been diagnosed with precancerous polyps, or adenomas. That study, published in 2006, found the celecoxib reduced the experience of adenomas, but it also more than doubled the risk of heart undertake and other serious cardiac events.
Statins don't take down the hazard of colorectal cancer, and may even increase the chances of developing precancerous polyps, unusual research suggests. Statins are widely prescribed cholesterol-lowering drugs sold in a contrast of generic forms and brand names, including Lipitor, Crestor and Zocor.
Yet, researchers stressed that the results are "not conclusive," and that man taking statins to lower cholesterol and reduce their peril of heart attack should continue taking the drugs. "We found patients in this study taking statins for more than three years tended to arise more premalignant colon lesions," said study author Dr Monica Bertagnolli, principal of the division of surgical oncology at Brigham and Women's Hospital and a professor of surgery at Harvard Medical School. "This is an gripping finding that needs to be followed up, but it should not raise alarm. No one should dam taking their statins."
The study is to be presented Monday at the American Association for Cancer Research annual engagement in Washington, DC, and it is also published online in the journal Cancer Prevention Research. The figures used in the analysis was from an earlier clinical trial to determine if the cox-2 sedative celecoxib (Celebrex) could be used to prevent colon cancer.
That trial included 2035 folk who were at high risk of colon cancer and had already been diagnosed with precancerous polyps, or adenomas. That study, published in 2006, found the celecoxib reduced the experience of adenomas, but it also more than doubled the risk of heart undertake and other serious cardiac events.
Subscribe to:
Posts (Atom)